$53.13
0.27% today
Nasdaq, Nov 04, 09:15 pm CET
ISIN
US80105N1054
Symbol
SNY
Sector
Industry

Sanofi Sponsored ADR Stock News

Negative
Forbes
5 days ago
On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.
Neutral
Business Wire
7 days ago
TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead investigational candidate, RES-010, through a Phase 2 proof-of-concept clinical trial. RES-010 represents a first-in-class antisense oligonucleotide targeting miR-22, a non-coding RNA that plays a pivota...
Positive
The Motley Fool
10 days ago
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Neutral
Seeking Alpha
10 days ago
Sanofi (NASDAQ:SNY ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Thomas Kudsk - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Ex...
Positive
Investors Business Daily
10 days ago
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Positive
Reuters
11 days ago
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Neutral
GlobeNewsWire
11 days ago
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Neutral
GlobeNewsWire
11 days ago
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spont...
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today